Keywords
obesity
non-alcoholic steatohepatitis
olmesartan
telmisartan
atorvastatin
Abstract
The results of treatment of patients with arterial hypertension and obesity combined with non-alcoholic steatohepatitis are presented in article. Herein, the combined use of olmesartan or telmisartan with atorvastatin for 12 weeks had a positive impact on the physical condition of patients with arterial hypertension and obesity. This effect was manifested by maintenance of optimal blood pressure, the reduction of subjective complaints and the improvement of heart hemodynamics. Administration of sartans and statins to patients with arterial hypertension combined with obesity and non-alcoholic steatohepatitis led to a significant reduction of LDL (p<0.01) and LDL cholesterol levels (p<0.01), as well as the values of leptin (p<0.01) and IL-6 (p<0.01). The combination of olmesartan or telmisartan with atorvastatin not only allows a control of BP, but also a reduction of the pro-atherogenic fractions of blood lipids, hyperleptinaemia and levels of pro-inflammatory IL-6, hence, in this manner, improving the patient general condition.
References
1. Amosova E.N.: From the treatment of atherosclerosis by modifying the forecast: Focus on lipidlowering therapy. Chapter 1. Sertse i sudyny, 33, 6, 2011
2. Bablyak S.D. Khomyn A.M.: An experience of the use of combined antihypertensive therapy in aged women with long) lasting arterial hypertension. Medytsyna transportu Ukrainy, 2, 64, 2008.
3. Boychak M.P.: Additional effects of angiotensin II receptor antagonists in the treatment of patients with hypertension. Therapia, 54, 37, 2011.
4. Egorov I.E.: Hypertension: the evolution of approaches to treatment. Health of Ukraine, 2, 67, 2013.
5. Gerasimova A.S., Oleinikov V.E., Yeliseyeva I.V.: The peculiarities of arterial hypertension course and involvement of the target organs in metabolic syndrome. International Medical Journal, 3, 22, 2008
6. Gubergrits N.B. Lareva N.V.: Statins in hepatology: a «princess frog» or a «toad»? Contemporary gastroenterology [Suchasna gastroenterologia], 6, 78, 2011
7. Ikejima H. et al.: Effects of telmisartan, a unique angiotensin receptor blocker with selective prexisome proliferatoractivated receptor-gamma-modulating activity, on nitric oxide bioavaliability and atherosclerotic change. J. Hypertens, 26, 964, 2008.
8. Khukhlina O.S., Gorbatiuk I.B.: The investigation of rosuvastatin and mosaprid influence on the changes of the blood lipid profile, the level of insulin resistance and bilelithogenicity in patients with chronic stone–free cholecystitis, in combination with obesity and ischemic heart disease. Clin. and expirem. Pathol., 10, 143, 2011.
9. Kubik M. et al.: Telmisartan improves cardiometabolic profile in obese patients with arterial hypertension. Kidney Blood Press. Res., 35, 281, 2012.
10. Mitchenko O.I. et al.: Leptin adiponectin index as a new additional surrogate marker of atherosclerotic lesions. Ukraiinskyj cardiologichnyj zhurnal, 2, 40, 2012.
11. Nakayama S. et al.: Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension. Hypertens Res., 31, 7, 2008.
12. Neutel J.M.: Choosing among reninangiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy. Current Medical Research & Opinion, 26, 213, 2010.
13. Pérez-Castrillón J.L. et al.: Telmisartan effect’s on remodelling bone markers in hypertensive patients. Nutr Hosp., 27, 276, 2012.
14. Solomenchyk T.M. et al.: Efficacy of Rosuvastatin in patients with hypertension of high cardiovascular risk. Liky Ukrainy, 9-10, 82, 2013.
15. The ONTARGET investigators. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med., 358, 1547, 2008.
16. The TRANSCEND investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet, 372, 1174, 2008.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
Copyright (c) 2017 Authors